SmurfVA's Random Picks

[Ned Serious]

SYN: Data due this week for top-line data from its Trimesta/Copaxone combo Phase II multi-center clinical trial, any time from now until Presentation on Tuesday/Wednesday afternoon.

Data may be PR'd anytime now since the embargo that the AAN had which prevented early data releases, expired on Friday. As some may know CYTK is also going to be presenting at AAN. CYTK announced failed results on Friday before the market opened. Their stock plummeted 64% on Friday.

SYN's stocked dropped on Friday. So did the market and many bios. There was a email sent out by Seeking Alpha which mistakenly stated that SYN was having a reverse stock split. It was not SYN, it was another company with a similar symbol. Also, I believe that $heff sold his remaining shares on an automatic stop loss.

SYN has made a nice recovery lately from the Bio selloff. It would be understandable that anyone who saw the CYTK failed results and stock price drop would be anxious and might sell some, or all just in case of bad data.

At the moment, I'm holding 4,000 shares. SYN didn't PR failed results on Friday, even though they had the opportunity as well. That doesn't mean that they will have positive results this week. But perhaps it does push it in its favor a little. I read a post this week that PGNX presented failed data at a presentation once. I don't know if that's true and wasn't able to verify. So, who knows?

At the moment, I plan on holding all my shares through data release, whenever that may be. My plans may change at any moment. SYN recently cancelled an equity agreement in which they could have raised cash.

For anyone interested in SYN and one of its investor's; Randall Kirk, here's some good info: http://stockmatusow.com/following-the-smart-money-the-small-cap-biotech-investments-of-randal-j-kirk/ (scroll down page for SYN section).

Best of Luck and thoughts always appreciated. I have no price targets if data is good, except that it should be above what it is now.
-------------------------------------------

SYN is presenting at the American Academy of Neurology:

American Academy of Neurology - Rhonda Voskuhl, M.D. - Topline Phase II Trimesta Results for Relapsing-Remitting MS
Tuesday, April 29, 2014 - Wednesday, April 30, 2014

Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta™, for the treatment of relapsing-remitting multiple sclerosis (MS), will present topline results at the American Academy of Neurology's (AAN) 66th Annual Meeting in Philadelphia. The abstract titled, A Combination Trial of Estriol Plus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis, will be presented as part of the AAN Emerging Science program during two sessions, as follows:

MS and CNS Inflammatory Disease: Novel Therapeutics
Presentation: 003
Event Date: Tuesday, April 29, 2014
Presentation Time: 3:45 p.m. (ET)

Emerging Therapeutic Advances in Multiple Sclerosis
Presentation: 002
Event Date: Wednesday, April 30, 2014
Presentation Time: 5:35 p.m. (ET)
No webcast available.